M Holdings Securities Inc. lessened its stake in GSK plc (NYSE:GSK – Get Rating) by 5.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 9,062 shares of the pharmaceutical company’s stock after selling 519 shares during the quarter. M Holdings Securities Inc.’s holdings in GSK were worth $267,000 at the end of the most recent quarter.
A number of other hedge funds also recently made changes to their positions in GSK. Pflug Koory LLC acquired a new position in shares of GSK during the 3rd quarter valued at $26,000. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its holdings in shares of GSK by 61.3% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 968 shares of the pharmaceutical company’s stock valued at $42,000 after acquiring an additional 368 shares in the last quarter. Householder Group Estate & Retirement Specialist LLC acquired a new position in shares of GSK during the 3rd quarter valued at $31,000. CoreCap Advisors LLC acquired a new position in shares of GSK during the 2nd quarter valued at $66,000. Finally, Zullo Investment Group Inc. lifted its holdings in shares of GSK by 21.3% during the 2nd quarter. Zullo Investment Group Inc. now owns 1,762 shares of the pharmaceutical company’s stock valued at $77,000 after acquiring an additional 309 shares in the last quarter. Institutional investors and hedge funds own 13.15% of the company’s stock.
GSK Price Performance
GSK opened at $33.58 on Thursday. The company has a 50-day moving average of $35.03 and a 200-day moving average of $33.55. The company has a market capitalization of $68.74 billion, a P/E ratio of 3.91, a PEG ratio of 1.68 and a beta of 0.65. GSK plc has a 1-year low of $28.47 and a 1-year high of $46.97. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.68 and a current ratio of 0.91.
GSK Cuts Dividend
Wall Street Analysts Forecast Growth
Several equities analysts recently weighed in on GSK shares. AlphaValue upgraded shares of GSK to a “buy” rating in a report on Thursday, December 8th. The Goldman Sachs Group initiated coverage on shares of GSK in a research note on Sunday, February 26th. They set a “buy” rating on the stock. TheStreet raised shares of GSK from a “c+” rating to a “b-” rating in a research note on Friday, December 30th. Berenberg Bank lifted their price target on shares of GSK from GBX 1,580 ($19.26) to GBX 1,730 ($21.08) in a research note on Friday, February 10th. Finally, JPMorgan Chase & Co. lifted their price target on shares of GSK from GBX 1,350 ($16.45) to GBX 1,400 ($17.06) in a research note on Thursday, February 2nd. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, GSK has an average rating of “Hold” and a consensus price target of $1,576.88.
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.
- Get a free copy of the StockNews.com research report on GSK (GSK)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSK – Get Rating).
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.